Anthem Biosciences Share Price Today (ANTHEM)
TODAY IN ONE LINE
ANTHEM fell 1.0% on light volume, in line with Nifty's -0.4% move, supported by recent strong earnings.
With a market cap of ₹43,397.53 Cr., it trades at a P/E of 75.11. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Anthem Biosciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 127.2% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 26.4% and Profit up 129.0%
- ●High Capital EfficiencyROCE of 30.4% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 22.3%
- ●Healthy Operating MarginsOPM is structurally strong at 39.3%
- ●High Promoter HoldingPromoters hold 74.7% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 72.6x
Latest Anthem Biosciences News
What changed recently?
Recent events, corporate actions, and announcements.
Anthem Biosciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Anthem Biosciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Anthem Biosciences Limited trades at a P/E of 75.11× and P/B of 14.22×, against the Healthcare sector median P/E of 44.57×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Anthem Biosciences Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Anthem Biosciences Limited — derived from the live tape, not yesterday's close.
Anthem Biosciences Limited last traded at ₹769.9 with an intraday range of ₹767.35–₹779.4 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹769.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 801.18 | +31.28 | +4.06% |
| R3 | 789.13 | +19.23 | +2.50% |
| R2 | 784.27 | +14.37 | +1.87% |
| R1 | 777.08 | +7.18 | +0.93% |
| PIVOT | 772.22 | 2.32 | 0.30% |
| CURRENT | 769.90 | — | — |
| S1 | 765.03 | -4.87 | -0.63% |
| S2 | 760.17 | -9.73 | -1.26% |
| S3 | 752.98 | -16.92 | -2.20% |
| S4 | 740.93 | -28.97 | -3.76% |
ANTHEM is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹767.35–₹779.4
Trading Inside opening range
Anthem Biosciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Anthem Biosciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Anthem Biosciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹43,397.53 Cr. and reported EPS of ₹10.13.
| Metric | — | Mar 2026 |
|---|---|---|
| Revenue from Operations | — | 2,124 |
| Other Income | — | 156 |
| Total Income | — | 2,280 |
| — | 812 | |
| Gross ProfitDerived | — | 1,312 |
| Gross Margin %Derived | — | 61.76% |
| — | 478 | |
| EBITDA (Operating Profit)Derived | — | 834 |
| OPM %Derived | — | 39.25% |
| — | 117 | |
| Profit Before Tax (PBT) | — | 824 |
| — | 232 | |
| Effective Tax %Derived | — | 28.20% |
| Total Profit for Period | — | 592 |
| Net Profit (Owner's PAT)Derived | — | 592 |
| Net Profit Margin %Derived | — | 27.86% |
| Earnings Per Share (EPS ₹) | — | 10.54 |
| Diluted Shares Outstanding (Cr) | — | 56 |
| Other Comprehensive Income (Net of Tax) | — | -2 |
| Total Expenses (incl. D&A & Interest) | — | 1,456 |
| Material Cost % of RevenueDerived | — | 33.59% |
| Employee Cost % of RevenueDerived | — | 13.31% |
| Other Cost % of RevenueDerived | — | 9.20% |
| Interest Coverage (x)Derived | — | 101.50x |
| Period | Mar 2026 | Trend |
|---|---|---|
| Revenue from Operations | 2,124 | |
| Other Income | 156 | |
| Total Income | 2,280 | |
812 | ||
| Gross ProfitDerived | 1,312 | |
| Gross Margin %Derived | 61.76% | |
478 | ||
| EBITDA (Operating Profit)Derived | 834 | |
| OPM %Derived | 39.25% | |
117 | ||
| Profit Before Tax (PBT) | 824 | |
232 | ||
| Effective Tax %Derived | 28.20% | |
| Total Profit for Period | 592 | |
| Net Profit (Owner's PAT)Derived | 592 | |
| Net Profit Margin %Derived | 27.86% | |
| Earnings Per Share (EPS ₹) | 10.54 | |
| Diluted Shares Outstanding (Cr) | 56 | |
| Other Comprehensive Income (Net of Tax) | -2 | |
| Total Expenses (incl. D&A & Interest) | 1,456 | |
| Material Cost % of RevenueDerived | 33.59% | |
| Employee Cost % of RevenueDerived | 13.31% | |
| Other Cost % of RevenueDerived | 9.20% | |
| Interest Coverage (x)Derived | 101.50x |
Anthem Biosciences segment analysis : revenue and profit mix.
Disclosed business segments at Anthem Biosciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Anthem Biosciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Anthem Biosciences Limited.
Our AI distills the core fundamental drivers supporting Anthem Biosciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Anthem Biosciences Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Latest quarterly EPS grew 129.7% YoY, demonstrating exceptional earnings momentum and operational leverage.
Operating margin 32.94% TTM showcases industry-leading profitability and superior cost discipline.
ROCE 30.40% and ROE 22.30% signal highly efficient capital deployment and sustainable returns.
Debt-to-equity 0.0002x with net cash ₹220.71 Cr indicates fortress balance sheet and financial flexibility.
Promoter holding 74.68% ensures strong alignment with long-term shareholder value creation.
Key Risks.
P/E ratio 72.60x and forward P/E 48.88x signal significant overvaluation versus biotech peers.
Dividend yield 0.25% with payout ratio 19.23% offers minimal income to shareholders.
Stock near 52-week high ₹873.50, trading at 89% of peak limits near-term upside potential.
PEG ratio 21.46x far exceeds 1.0 threshold, indicating stretched valuation relative to growth.
EV/EBITDA 36.50x and EV/FCF 19.83x premium valuations vulnerable to earnings disappointment.
Flip Conditions.
Valuation risk. a P/E above 98 (~2.2× the sector multiple of 44.6) would leave less room for earnings disappointment.
Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.
Watch wage inflation and attrition rates — primary threats to operating leverage in IT.
Return-quality risk. ROE below 17% would indicate weaker capital compounding.
Anthem Biosciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Anthem Biosciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Anthem Biosciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Anthem Biosciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Anthem Biosciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Anthem Biosciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Anthem Biosciences Limited stood at 68.3% of traded volume, against a 20-day average of 60.8%.
Anthem Biosciences announcements: results, concalls, ratings, M&A.
Filings Anthem Biosciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Anthem Biosciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 68 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Anthem Biosciences Limited has informed the Exchange about Schedule of meet
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Anthem Biosciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Disclosure under SEBI Takeover Regulations
Anthem Biosciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Updates
Anthem Biosciences Limited has informed the Exchange regarding the Letter to Shareholders providing the weblink and navigation path for accessing the…
Credit Rating
Anthem Biosciences Limited has informed the Exchange about Credit Rating
Investor decks & rating reports.
Anthem Biosciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Anthem Biosciences has declared, sequenced by announce and record date.
Anthem Biosciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Anthem Biosciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Anthem Biosciences as reported to SEBI — buying and selling signals from the people who know the business best.
Anthem Biosciences insider activity below tracks 9 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Krithika Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Viridity Tone LLP | Insider | 09 Mar 2026 | buy | +2.03 Cr | ₹1,255.25 Cr. | ₹617.93 |
| Aruna Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Krithika Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Viridity Tone LLP | Insider | 09 Mar 2026 | buy | +2.03 Cr | ₹1,255.25 Cr. | ₹617.93 |
| Aruna Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Krithika Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
| Viridity Tone LLP | Insider | 09 Mar 2026 | buy | +2.03 Cr | ₹1,255.25 Cr. | ₹617.93 |
| Aruna Ganesh | Insider | 09 Mar 2026 | buy | +85.57 L | — | — |
About Anthem Biosciences Limited: business, sector, key facts.
What Anthem Biosciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Anthem Biosciences Limited operates in the Biotechnology industry under the Healthcare sector, listed as NSE: ANTHEM, BSE: 544449.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Anthem Biosciences Limited (ANTHEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Anthem Biosciences Limited (ANTHEM)?
The current share price of Anthem Biosciences Limited (ANTHEM) is ₹769.9. Today, the stock has declined by ₹7.95 (1.02%), trading in a range of ₹767.35 to ₹779.4. The stock opened at ₹775.1 with a trading volume of 2,42,556 shares.
02Is Anthem Biosciences Limited stock a good investment for long-term?
Anthem Biosciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹43,397.53 crores, P/E ratio of 75.11, ROE of 22.30%, and ROCE of 30.40%. The dividend yield stands at 0.25%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Anthem Biosciences Limited stock?
The 52-week high price of Anthem Biosciences Limited (ANTHEM) is ₹873.5, while the 52-week low is ₹579.15. Currently trading at ₹769.9, the stock is 64.8% away from its 52-week low and 11.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Anthem Biosciences Limited stock at the current price?
Whether to buy Anthem Biosciences Limited stock at ₹769.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 75.11 and P/B ratio of 14.22. Today's performance shows a loss of 1.02%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Anthem Biosciences Limited and when is the next dividend?
Anthem Biosciences Limited offers a dividend yield of 0.25%, which means for every ₹100 invested at the current price of ₹769.9, you can expect to receive approximately ₹0.25 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Anthem Biosciences Limited?
Anthem Biosciences Limited's key financial metrics include: P/E Ratio: 75.11, P/B Ratio: 14.22, ROE: 22.30%, ROCE: 30.40%, Dividend Yield: 0.25%, EPS: ₹10.13, Book Value: ₹54.17, and Debt-to-Equity: 0.02. The company's market cap stands at ₹43,397.53 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Anthem Biosciences Limited stock performing today in the market?
Anthem Biosciences Limited stock opened at ₹775.1 and is currently trading at ₹769.9, showing a decline of ₹7.95 (1.02%). The intraday high is ₹779.4 and low is ₹767.35. The trading volume stands at 2,42,556 shares, indicating moderate market participation today.
08What is the P/E ratio of Anthem Biosciences Limited and what does it indicate?
Anthem Biosciences Limited has a Price-to-Earnings (P/E) ratio of 75.11, which means investors are willing to pay ₹75.11 for every ₹1 of earnings. With an EPS of ₹10.13, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Anthem Biosciences Limited (ANTHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.